Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.
FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a latent unmet clinical need for patients with the Human Papilloma Virus (HPV). As the largest pharma industry event worldwide, CPHI Frankfurt will allow thousands of participants to have a first look at this innovative product, whose exclusive formula helps to counteract the signs, symptoms, and persistence of HPV.
- Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners.
- Pervistop promises to be an extremely effective tool in the management of an exceedingly unpredictable disease.
- HPV is the most common sexually transmitted infection worldwide, and it is known to cause certain cancers and genital warts.
- Pharma International is committed to supporting our Partners through equitable, exclusive distribution agreements, while sharing the scientific know-how and marketing strategies, which are needed to be successful.